Inhaled Cidofovir Dry-Powder Formulation for Postexposure Prophylaxis and Treatment of Smallpox
Award Notice Posted
- Solicitation number
- BAA-DMID-NIAID-BARDA
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Awarded
- to Resilience Government Services, Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- HHSN272200900015C Federal contract award
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- PSC
- Not on record
- Place of performance
- Nanotherapeutics, Inc. 13859 Progress Boulevard, Suite 300 Alachua, Florida 32615, United States
Notice details come from SAM.gov. Updated .
Notice text
2 versions
Update #2 · Latest ·
Nanotherapeutics and its subcontractors propose to develop an inhaled cidofovir delivery system as a dry-powder formulation for the smallpox therapeutic indication. Nanotherapeutics and its subcontractors shall: (1) prepare NanoFOVIR cidofovir dry-powder inhaled formulations and compare inhaled administration in vivo at different doses and dosing schedules for proof of concept efficacy studies; (2) conduct preclinical development of the NanoFOVIR to asses the safety / acute toxicology of the drug in animal studies and to scale-up and manufacture one lead inhaled dosage from and (3) file an Investigational New Drug (IND) Application with the Food and Drug Administration (FDA) to enable a phase I Clinical safety evaluation of the drug.
Period: August 15th, 2009 through August 14, 2014
Contract Type: Cost Plus Fixed Fee
Contract Award Date: 8/15/09 - Unable to apply old date.
Update #1 ·
Posted incorrectly, reposting.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity